Loading clinical trials...
Loading clinical trials...
A Phase 2, Multicenter, Randomized, Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of Ataluren (PTC124) for the Treatment of Nonsense Mutation Aniridia
Conditions
Interventions
Ataluren
Placebo
Locations
3
United States
Casey Eye Institute, Oregon Health & Science University
Portland, Oregon, United States
University of Virginia
Charlottesville, Virginia, United States
University of British Columbia
Vancouver, British Columbia, Canada
Start Date
January 31, 2016
Primary Completion Date
January 22, 2021
Completion Date
January 22, 2021
Last Updated
May 27, 2022
NCT05390801
NCT05909735
NCT04117880
Lead Sponsor
PTC Therapeutics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions